GIPR and type 2 diabetes mellitus: Next, we sought to link the molecular pharmacology of the GIPR variants to cardiometabolic phenotypes using Danish cohorts (T2D: DD2 and Inter99, N = 7,173 and quantitative traits: Inter99, N = 5,711) and the UK Biobank18 (465,506 whole-exome-sequenced participants).